Down-regulated Expression of NPM1 in IMS-M2 Cell Line by (-)-epigallocatechin-3-gallate

Overview

Journal Asian Pac J Trop Biomed

Specialty Tropical Medicine

Date 2014 Sep 4

PMID 25183279

Citations 4

Authors

Hoang Thanh Chi

Bui Thi Kim Ly

Hoang Anh Vu

Yuko Sato

Phu Chi Dung

Phan Thi Xinh

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations.

Methods: Cell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western blot analysis were performed to test the protein expression of NPM1, AKT, those associated with apoptosis.

Results: EGCG can down-regulate the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Moreover, EGCG also suppressed the cell proliferation and induced apoptosis in IMS-M2 cells.

Conclusions: The results suggested that EGCG could be considered as a reagent for treatment of AML patients with NPM1 mutations.

Citing Articles

Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia?.

Florio D, Marasco D Int J Mol Sci. 2024; 25(2).

PMID: 38255885 PMC: 10815591. DOI: 10.3390/ijms25020811.

Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Ranieri R, Pianigiani G, Sciabolacci S, Perriello V, Marra A, Cardinali V Leukemia. 2022; 36(10):2351-2367.

PMID: 36008542 PMC: 9522592. DOI: 10.1038/s41375-022-01666-2.

Nucleophosmin in Its Interaction with Ligands.

Cela I, Di Matteo A, Federici L Int J Mol Sci. 2020; 21(14).

PMID: 32664415 PMC: 7402337. DOI: 10.3390/ijms21144885.

Molecules that target nucleophosmin for cancer treatment: an update.

Di Matteo A, Franceschini M, Chiarella S, Rocchio S, Travaglini-Allocatelli C, Federici L Oncotarget. 2016; 7(28):44821-44840.

PMID: 27058426 PMC: 5190137. DOI: 10.18632/oncotarget.8599.

References

Yu Y, Maggi Jr L, Brady S, Apicelli A, Dai M, Lu H . Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 2006; 26(10):3798-809. PMC: 1488996. DOI: 10.1128/MCB.26.10.3798-3809.2006. View

Gimenez M, de Oliveira Souza V, Izumi C, Barbieri M, Chammas R, Oba-Shinjo S . Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin. Proteomics. 2010; 10(15):2812-21. DOI: 10.1002/pmic.200900722. View

Chi H, Ly B, Kano Y, Tojo A, Watanabe T, Sato Y . ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412. Biochem Biophys Res Commun. 2012; 429(1-2):87-92. DOI: 10.1016/j.bbrc.2012.10.087. View

Mah Y, Song J, Kim S, Lee J, Jeon M, Jung U . The effect of epigallocatechin-3-gallate (EGCG) on human alveolar bone cells both in vitro and in vivo. Arch Oral Biol. 2014; 59(5):539-49. DOI: 10.1016/j.archoralbio.2014.02.011. View

Qian Z, Joslin J, Tennant T, Reshmi S, Young D, Stoddart A . Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2009; 184(1-2):50-7. PMC: 4642715. DOI: 10.1016/j.cbi.2009.11.025. View

Jian Y, Gao Z, Sun J, Shen Q, Feng F, Jing Y . RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene. 2009; 28(47):4201-11. DOI: 10.1038/onc.2009.275. View

Chi H, Vu H, Iwasaki R, Thao L, Hara Y, Taguchi T . Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells. Cancer Biol Ther. 2009; 8(20):1934-9. DOI: 10.4161/cbt.8.20.9594. View

Lindstrom M . NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling. Biochem Res Int. 2010; 2011:195209. PMC: 2989734. DOI: 10.1155/2011/195209. View

Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K . Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005; 437(7055):147-53. DOI: 10.1038/nature03915. View

10.

Daver N, Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N . Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013; 13(4):435-40. PMC: 4114766. DOI: 10.1016/j.clml.2013.02.021. View

11.

Li Z, Hann S . The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle. 2009; 8(17):2703-7. PMC: 3234343. DOI: 10.4161/cc.8.17.9418. View

12.

Iwasaki R, Ito K, Ishida T, Hamanoue M, Adachi S, Watanabe T . Catechin, green tea component, causes caspase-independent necrosis-like cell death in chronic myelogenous leukemia. Cancer Sci. 2009; 100(2):349-56. PMC: 11159957. DOI: 10.1111/j.1349-7006.2008.01046.x. View

13.

Falini B, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli M . Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. Blood Rev. 2011; 25(6):247-54. DOI: 10.1016/j.blre.2011.06.001. View

14.

Falini B, Martelli M, Bolli N, Sportoletti P, Liso A, Tiacci E . Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood. 2010; 117(4):1109-20. DOI: 10.1182/blood-2010-08-299990. View

15.

Mitrea D, Grace C, Buljan M, Yun M, Pytel N, Satumba J . Structural polymorphism in the N-terminal oligomerization domain of NPM1. Proc Natl Acad Sci U S A. 2014; 111(12):4466-71. PMC: 3970533. DOI: 10.1073/pnas.1321007111. View

16.

Quentmeier H, Martelli M, Dirks W, Bolli N, Liso A, MacLeod R . Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005; 19(10):1760-7. DOI: 10.1038/sj.leu.2403899. View

17.

Leal M, Mazzotti T, Calcagno D, Cirilo P, Martinez M, Demachki S . Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. BMC Gastroenterol. 2014; 14:9. PMC: 3893589. DOI: 10.1186/1471-230X-14-9. View

18.

Liu Y, Zhu H, Ruan G, Qin Y, Shi H, Lai Y . NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. Leuk Res. 2013; 37(7):737-41. DOI: 10.1016/j.leukres.2013.03.009. View

19.

Tsao A, Liu D, Martin J, Tang X, Lee J, El-Naggar A . Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009; 2(11):931-41. PMC: 4243312. DOI: 10.1158/1940-6207.CAPR-09-0121. View

20.

Balusu R, Fiskus W, Rao R, Chong D, Nalluri S, Mudunuru U . Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood. 2011; 118(11):3096-106. PMC: 6710561. DOI: 10.1182/blood-2010-09-309674. View